

Wiggin and Dana LLP
One City Place
185 Asylum Street
Hartford, Connecticut
06103-3402

860.297.3700
860.525.9380 fax
www.wiggin.com

RECEIVED
CENTRAL FAX CENTER

SEP 11 2007

WIGGIN AND DANA

Counsellors at Law

Telefax Transmittal

Date:

September 11, 2007

To / Company / Telefax:

USPTO - Commissioner for Patents
571-273-8300

From:

Todd E. Garabedian, Ph.D.

Telephone / Email:

860.297-3716 / tgarabedian@wiggin.com

Client / matter code:

185160 / 10

Please copy:

We will copy:

This message is intended for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential and exempt from disclosure. If the reader of this message is not the intended recipient or an employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this message is strictly prohibited. If you have received this communication in error please notify us immediately by telephone and return the original message to us by mail. Thank you.

Special Instructions

In re Application of: Mats Hellström et al. Docket No.: 0208/76419-PCT-US/RDK

Application No. : 10/581,761

Filed : June 5, 2006

Our Reference: 102959-202

Assignee : AngioGenetics Sweden AB

Title: ANGIOGENESIS AFFECTING POLYPEPTIDES, PROTEINS, AND
COMPOSITION, AND METHODS OF USE THEREOF

Enclosed are:

- (1) Transmittal Letter (1 page); and
- (2) Revocation of original power of attorney and grant of new power of attorney and change of correspondence address (3 pages).

\\18516\\10\\55239.1

4 page(s) following this page

SEP 11 2007
PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: MATS HELLSTRÖM
ELISABET WALLGARD
MATTIAS KALÉN

Serial No.: 10/581,761

Filed: June 5, 2006

Assignee: AngioGenetics Sweden AB

Customer No.: 27267

Title: ANGIOGENESIS AFFECTING POLYPEPTIDES, PROTEINS, AND
COMPOSITION, AND METHODS OF USE THEREOF

Docket: 0208/76419-PCT-US/RDK

Art Unit:

Examiner:

Conf. No.:

Our Reference 102959-202

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Enclosed please find the following document(s) regarding the above-identified patent application:

1. REVOCATION OF POWER OF ATTORNEY, GRANT OF NEW POWER OF ATTORNEY, AND CHANGE OF CORRESPONDENCE ADDRESS (INCLUDES STATEMENT UNDER 37 C.F.R. § 3.73(b) (3 pages).

Respectfully submitted,

Date: 11 SEPT 2007, 2007

By: Todd E. Garabedian
Todd E. Garabedian, Ph.D., Reg. No. 39,197

Wiggin and Dana LLP
One Century Tower
P.O. Box 1832
New Haven, CT 06508
Tel. No. (860) 297-3716

\\18516\\10\\55237.1

CERTIFICATE OF MAILING OR TRANSMISSION (37 CFR 1.8(a))

I hereby certify that this correspondence (along with any paper referred to as being attached or enclosed) is being:

- ☐ deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
- ☒ transmitted by facsimile on the date shown below to the United States Patent and Trademark Office via facsimile at (571) 273-8300.

Date: 11 SEPT, 2007

Signed:

Todd E. Garabedian
Todd E. Garabedian, Ph.D.

SEP 11 2007

Our Docket No.: 102959-202
Page 1 of 3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: MATS HELLSTRÖM
ELISABET WALLGARD
MATTIAS KALÉN

Serial No.: 10/581,761
Filed: June 5, 2006
Assignee: AngioGenetics Sweden AB
Customer No.: 27267
Title: ANGIOGENESIS AFFECTING POLYPEPTIDES, PROTEINS, AND COMPOSITION, AND METHODS OF USE THEREOF

Docket: 0208/76419-PCT-US/RDK
Art Unit:
Examiner:
Conf. No.:
Our Reference 102959-202

REVOCATION OF POWER OF ATTORNEY, GRANT OF NEW POWER OF ATTORNEY, AND CHANGE OF CORRESPONDENCE ADDRESS
(INCLUDES STATEMENT UNDER 37 C.F.R. §3.73(b))

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

AngioGenetics Sweden AB, of Stockholm, Sweden ("Assignee"), organized under the laws of Sweden, states that it is the current Assignee of the entire right, title, and interest to the above-identified U.S. patent application by virtue of a chain of title as follows:

CERTIFICATE OF MAILING OR TRANSMISSION (37 CFR 1.8(a))	
I hereby certify that this correspondence (along with any paper referred to as being attached or enclosed) is being:	
<input type="checkbox"/>	deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
<input checked="" type="checkbox"/>	transmitted by facsimile on the date shown below to the United States Patent and Trademark Office via facsimile at (571) 273-8300.
Date: <u>11 SEPT</u> , 2007	Signed: <u>Todd E. Garabedian</u> Todd E. Garabedian, Ph.D.

Our Docket No.: 102959-202
Page 2 of 3

1. From: Mats Hellström
Elisabet Wallgard
Mattias Kalén

To: AngioGenetics Sweden AB

The document was recorded in the United States Patent and Trademark Office
at Reel: 019168, Frame: 0474.

The undersigned is empowered to sign this statement on behalf of the Assignee.

Assignee hereby revokes all previous powers of attorney or authorization of agent
given in this U.S. patent application.

Assignee hereby appoints the practitioners of Wiggin and Dana LLP, who are
identified by the U.S. Patent & Trademark Office under Customer Number 27267 and to
transact all business in the Patent and Trademark Office connected therewith.

Please address all future written and fax correspondence to Customer Number:




27267

PATENT TRADEMARK OFFICE

Patent Docket Coordinator
WIGGIN and DANA LLP
One Century Tower
P.O. Box 1832
New Haven, CT 06508-1832
Telephone: (203) 498-4400
Facsimile : (203) 782-2889

Our Docket No.: 102959-202
Page 3 of 3

Please direct all phone and email communications to Todd E. Garabedian, Ph.D., Reg. No. 39,197 at Wiggin and Dana LLP, phone: 860-297-3716 and email: tgarabedian@wiggin.com.


Signature of authorized person
for AngioGenetics Sweden AB

By: Mats Hellström

Title: Chief Executive Officer

Date: 23 August, 2007

\\18516\\10\\55234.1